Skip to main content
SpringerLink
Log in

Emerging Treatment of Acute Coronary Syndromes with Platelet Glycoprotein IIB/IIIA Inhibitors

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fuster V, Badimon L, Badimon JJ, Cheseboro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242–250.

    Google Scholar 

  2. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence. Circulation 1998;97:211–218.

    Google Scholar 

  3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–671.

    Google Scholar 

  4. Leftkovits J, Topol EJ. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Cleve Clin J Med 1996;63:181–186.

    Google Scholar 

  5. Coller BS. Blockade of platelet glycoprotein IIb/IIIa receptor as an anti-thrombotic strategy. Circulation 1995;92: 2373–2380.

    Google Scholar 

  6. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757–1764.

    Google Scholar 

  7. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic, and therapeutic profile. J Am Coll Cardiol 1992;19:926–935.

    Google Scholar 

  8. Ellis SG, Roubin GS, King SBI. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372–379.

    Google Scholar 

  9. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956–961.

    Google Scholar 

  10. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade bby abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. J Am Coll Cardiol 1997;30:149–156.

    Google Scholar 

  11. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996;77:1045–1051.

    Google Scholar 

  12. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic event in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997;278:479–484.

    Google Scholar 

  13. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336: 1689–1696.

    Google Scholar 

  14. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734–741.

    Google Scholar 

  15. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429–1435.

    Google Scholar 

  16. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87–92.

    Google Scholar 

  17. IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349: 1422–1428.

    Google Scholar 

  18. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445–1453.

    Google Scholar 

  19. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386–2395.

    Google Scholar 

  20. Moliterno DJ, Harrington RA, Newby KL, et al. Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON study 1-year follow-up. J Am Coll Cardio 1998;31:208Abstract.

    Google Scholar 

  21. PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.

    Google Scholar 

  22. PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497.

    Google Scholar 

  23. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436–443.

    Google Scholar 

  24. Roe MT, Marso SP, Sapp SK, Peterson JG. Empiric use of IIb/IIIa blockade in acute coronary syndromes: Early and durable reduction in ischemic events with eptifibatide in patients who did not undergo coronary revascularization, Circulation 1998;98:505I.Abstract.

    Google Scholar 

  25. Mahaffey KW, Harrington RA, Graffagnino C, et al. Comparison of stroke rates in patients with acute coronary syndromes and patients with acute myocardial infarction. J Am Coll Cardiol 1998;31:406Abstract.

    Google Scholar 

  26. Lincoff AM, Harrington RA, Califf RM, et al. Clinical efficacy of integrelin in unstable angina is accompanied by a modest increase in hemorrhagic risk: The PURSUIT trial. J Am Coll Cardiol 1998;31:185Abstract.

    Google Scholar 

  27. Giugliano RP, Hyatt RRJ. Thrombocytopenia with GP IIb/IIIa inhibitors: A meta analysis. J Am Coll Cardiol 1998;31:185Abstract.

    Google Scholar 

  28. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemosta 1997;78:214–219.

    Google Scholar 

  29. Deckers J, Califf RM, Topol EJ, Lincoff AM, Tcheng JE, Simoons ML. Use of abciximab (Reopro) is not associated with an increase in the risk of stroke: Overview of three randomized trials. J Am Coll Cardiol 1997;29:241Abstract.

    Google Scholar 

  30. Kleinman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Allergy Clin Immunol 1993;22:381–389.

    Google Scholar 

  31. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI investigators. Circulation 1997;95:846–854Abstract.

    Google Scholar 

  32. Moliterno DJ, Harrington RA, Krucoff MW, et al. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: The PARADIGM trial. Circulation 1996;94:I553Abstract.

    Google Scholar 

  33. Ronner E, van Kesteren HAM, Zijen P, et al. Combined therapy with streptokinase and integrelin. J Am Coll Cardiol 1998;31:191Abstract.

    Google Scholar 

  34. Braunwald E. TIMI 14 (Fibrinolytics 1 IIb/IIIa Blockade), American College of Cardiology 47th Annual Scienti~c Session, Atlanta, Georgia, 1998.

  35. Antman EM, Giugliano RP, McCabe CH, et al. Abciximab (Reopro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial. J Am Cardiol 1998;31:191Abstract.

    Google Scholar 

  36. Ohman EM. GUSTO-IV Pilot, American College of Cardiology 47th Annual Scientific Session, Atlanta, Georgia, 1998.

  37. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of the coagulation system in unstable angina and myocardial infarction. Circulation 1994;90:61–68.

    Google Scholar 

  38. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: Natural history and the effect of thrombolysis. Circulation 1998;97:26–33.

    Google Scholar 

  39. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76–81.

    Google Scholar 

  40. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117–21.

    Google Scholar 

  41. Deedwania PC, Ferguson JJ, Kereiakes DJ, et al. Sustained platelet GP IIb/IIIa blockade with oral orbo~ban: Interim safety and tolerability results of the SOAR study. J Am Coll Cardiol 1998;31:94A.

    Google Scholar 

  42. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation 1997;96: 1130–1138.

    Google Scholar 

  43. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998;97:340–349.

    Google Scholar 

  44. Giugliano RP, McCabe CH, Sequeira RF, et al. Dose ranging study of intravenous RPR 109891 in patients with acute coronary syndromes—results of TIMI 15A. J Am Coll Cardiol 1998;31:93Abstract.

    Google Scholar 

  45. Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety. Circulation 1998;97:312–314.

    Google Scholar 

  46. Braunwald E, Maseri A, Armstrong PW, et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Am Heart J 1998;135:S56–S66.

    Google Scholar 

  47. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996;94:629–635.

    Google Scholar 

  48. Goklaney AK, Murphy JD, Hillegass WB, Jr. Abciximab therapy in percutaneous intervention: Economic issues in the United States. Am Heart J 1998;135:S90–S97.

    Google Scholar 

  49. van Hout BA, Bowman L, Zelinger DJ, Simoons ML. Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Am Heart J 1998;135:S98–S106.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Matthew T. Roe & David J. Moliterno

Authors
  1. Matthew T. Roe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Moliterno
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roe, M.T., Moliterno, D.J. Emerging Treatment of Acute Coronary Syndromes with Platelet Glycoprotein IIB/IIIA Inhibitors. J Thromb Thrombolysis 7, 247–257 (1999). https://doi.org/10.1023/A:1008927025962

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008927025962

Keywords

Search

Navigation